Profil
Currently, Dámaso Molero is the Chief Executive Officer at 3P Biopharmaceuticals SL since 2006.
Formerly, the roles included Principal at Shionogi & Co., Ltd., Syntex, Inc., Glaxo, Inc., and Roche Holding AG.
Education includes undergraduate and MBA degrees from the University of Navarra.
Aktive Positionen von Dámaso Molero
| Unternehmen | Position | Beginn |
|---|---|---|
3P Biopharmaceuticals SL
3P Biopharmaceuticals SL Pharmaceuticals: MajorHealth Technology Develops therapeutic proteins and biological molecules | Vorstandsvorsitzender | 01.04.2007 |
Ehemalige bekannte Positionen von Dámaso Molero
| Unternehmen | Position | Ende |
|---|---|---|
| SHIONOGI & CO., LTD. | Corporate Officer/Principal | - |
| ROCHE HOLDING AG | Corporate Officer/Principal | - |
Syntex, Inc.
Syntex, Inc. MiscellaneousMiscellaneous Operates as a non-classified establishment | Corporate Officer/Principal | - |
Glaxo, Inc. | Corporate Officer/Principal | - |
Ausbildung von Dámaso Molero
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
Roche Holding AG
Roche Holding AG Pharmaceuticals: MajorHealth Technology Operates as a research-focused healthcare company with combined focus in pharmaceuticals and diagnostics | Health Technology |
Shionogi & Co., Ltd.
Shionogi & Co., Ltd. Pharmaceuticals: MajorHealth Technology Engages in the manufacturing and distribution of pharmaceuticals & diagnostic reagents | Health Technology |
University of Navarra
University of Navarra Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
3P Biopharmaceuticals SL
3P Biopharmaceuticals SL Pharmaceuticals: MajorHealth Technology Develops therapeutic proteins and biological molecules | Health Technology |
Syntex, Inc.
Syntex, Inc. MiscellaneousMiscellaneous Operates as a non-classified establishment | Miscellaneous |
Glaxo, Inc. |
















